Top health industry issues 2016 Issue 4: Goldilocks comes to drug prices

Mar 2016

The drug pricing mechanism and links to hospital income streams in China have been a long standing topic of discussion for the pharmaceutical industry. Increases in drug expenditure have posed a major challenge to a stable health environment, not least with regard to health insurance solvency. Consequently, drug prices form an important area of focus for health reform in China.

Also read the latest issues of our key findings and insights


Playback of this video is not currently available

Contact us

Mark Gilbraith

China & Hong Kong Management Consulting Leader, Health Industries Leader and Consumer & TMT Consulting Leader, PwC China

Tel: +[86] (21) 2323 2898

Jia Xu

Lead Consulting Partner of Pharma & Healthcare, PwC China

Tel: +[86] (10) 6533 7734